Mirabegron: A review of recent data and its prospects in the management of overactive bladder

Emilio Sacco*, Riccardo Bientinesi

*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivistaAbstract

65 Citazioni (Scopus)


Mirabegron is a novel, once-daily, orally active, first-in-class, potent β3-adrenoceptor agonist recently approved by Food and Drug Administration for overactive bladder therapy. Phase II studies and four large-scale phase III multinational randomized, controlled trials have supported the efficacy and tolerability of mirabegron in the clinical trial setting of patients with overactive bladder for up to 12 weeks of therapy and in the long term (12 months). The reported incidence and severity of treatment-emergent and serious adverse effects were similar to antimuscarinics, but with a more than threefold lower incidence of dry mouth compared with tolterodine. However, the effects on the cardiovascular system, pharmacokinetic interactions with other drugs, and increased incidence of new malignant events will require careful evaluation in the near future. © 2012, SAGE Publications. All rights reserved.
Lingua originaleEnglish
pagine (da-a)315-324
Numero di pagine10
RivistaTherapeutic Advances in Urology
Stato di pubblicazionePubblicato - 2012


  • efficacy
  • mirabegron
  • overactive bladder
  • safety
  • urinary incontinence
  • β3-adrenoceptor agonist


Entra nei temi di ricerca di 'Mirabegron: A review of recent data and its prospects in the management of overactive bladder'. Insieme formano una fingerprint unica.

Cita questo